LFG
ELVN icon

Larson Financial Group’s Enliven Therapeutics ELVN Stock Holding History

Larson Financial Group’s Portfolio ELVN Stock Details ELVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.1K Hold
61
– – ﹤0.01% 2966
2026
Q1 		$2.39K Sell
61
-45
-42% -$1.25K ﹤0.01% 2905
2025
Q4 		$1.63K Sell
106
-13
-11% -$259 ﹤0.01% 2822
2025
Q3 		$2.44K Hold
119
– – ﹤0.01% 2626
2025
Q2 		$2.39K Buy
+119
New +$2.25K ﹤0.01% 2351

Other funds holding ELVN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return

Larson Financial Group's ELVN Position: Q2 2026 in Review

Larson Financial Group held its Enliven Therapeutics (ELVN) position steady in Q2 2026 at 61 shares worth $3.1K. The position accounts for ﹤0.01% of the portfolio, ranked #2966.

Larson Financial Group first reported a position in ELVN in Q2 2025 and has held it in 5 quarters since. 211 funds tracked by Wall St. Rank hold ELVN as of Q2 2026.

  • Larson Financial Group held 61 shares of Enliven Therapeutics worth $3.1K as of Q2 2026.
  • Larson Financial Group left its Enliven Therapeutics share count unchanged in Q2 2026.
  • Enliven Therapeutics made up ﹤0.01% of Larson Financial Group's portfolio in Q2 2026, its #2966 holding.
  • Larson Financial Group first reported a position in Enliven Therapeutics in Q2 2025 and has held it in 5 quarters since.
  • 211 funds tracked by Wall St. Rank held Enliven Therapeutics as of Q2 2026.

Based on Larson Financial Group's 13F filing for Q2 2026, filed 14 Aug 2026.